pd 98059 has been researched along with irl 1620 in 2 studies
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 0 (0.00) | 18.2507 |
2000's | 2 (100.00) | 29.6817 |
2010's | 0 (0.00) | 24.3611 |
2020's | 0 (0.00) | 2.80 |
Authors | Studies |
---|---|
Callera, GE; Carneiro, FS; Carneiro, ZN; Ergul, A; Giachini, FR; Lima, VV; Tostes, RC; Webb, RC; Zemse, SM | 1 |
Ishida, K; Kamata, K; Kobayashi, T; Matsumoto, T; Nakayama, N | 1 |
2 other study(ies) available for pd 98059 and irl 1620
Article | Year |
---|---|
Interleukin-10 attenuates vascular responses to endothelin-1 via effects on ERK1/2-dependent pathway.
Topics: Animals; Aorta; Atrasentan; Blood Pressure; Endothelin A Receptor Antagonists; Endothelin-1; Endothelins; Flavonoids; Humans; Infusion Pumps, Implantable; Interleukin-10; Male; Mesenteric Arteries; Mice; Mice, Inbred C57BL; Mice, Knockout; Mitogen-Activated Protein Kinase 1; Mitogen-Activated Protein Kinase 3; Peptide Fragments; Phosphorylation; Protein Kinase Inhibitors; Pyrrolidines; Receptor, Endothelin A; Receptor, Endothelin B; Recombinant Proteins; RNA, Messenger; Signal Transduction; Time Factors; Tumor Necrosis Factor-alpha; Vasoconstriction | 2009 |
Involvement of NO and MEK/ERK pathway in enhancement of endothelin-1-induced mesenteric artery contraction in later-stage type 2 diabetic Goto-Kakizaki rat.
Topics: Angiotensin II; Animals; Arginine Vasopressin; Butadienes; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Disease Models, Animal; Disease Progression; Dose-Response Relationship, Drug; Endothelin-1; Endothelins; Enzyme Inhibitors; Extracellular Signal-Regulated MAP Kinases; Flavonoids; Male; MAP Kinase Kinase Kinases; Mesenteric Arteries; Nitric Oxide; Nitric Oxide Donors; Nitric Oxide Synthase; Nitriles; Nitroarginine; Nitroprusside; Oligopeptides; Peptide Fragments; Peptides, Cyclic; Piperidines; Rats; Rats, Wistar; Receptor, Endothelin A; Receptor, Endothelin B; Signal Transduction; Vasoconstriction; Vasodilation | 2009 |